bluebird bio Price Target, Predictions & Analyst Ratings

+0.64 (+3.62 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume2.65 million shs
Average Volume983,903 shs
Market Capitalization$1.24 billion
P/E RatioN/A
Dividend YieldN/A

bluebird bio (NASDAQ:BLUE) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Based on 19 Analyst Ratings

Analyst Price Target Consensus


High PT$93.00
Average PT$37.81
Low PT$18.00
9/19/20 to 9/19/21
1 Month Ago
8/20/20 to 8/20/21
3 Months Ago
6/21/20 to 6/21/21
1 Year Ago
9/20/19 to 9/19/20
Consensus Rating
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
6 Buy rating(s)
14 Buy rating(s)
17 Hold rating(s)
17 Hold rating(s)
12 Hold rating(s)
4 Hold rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$37.81$37.81$60.53$103.77
Price Target Upside106.40% Upside46.16% Upside60.61% Upside61.17% Upside
Get bluebird bio Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.

Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

bluebird bio (NASDAQ:BLUE) vs. Its Competitors

Typebluebird bioMedical CompaniesS&P 500
Consensus Rating Score
Consensus RatingHoldBuyBuy
Price Target Upside122.77% Upside8.38% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
Community Rating
Outperform Votes
Underperform Votes
Avg. Outperform Votes
Avg. Underperform Votes
Avg. Outperform Votes
Avg. Underperform Votes

bluebird bio (NASDAQ:BLUE) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/10/2021William Blair
R. Prasad
Initiated CoverageMarket Perform
8/10/2021BMO Capital Markets
Lower Price TargetMarket Perform$29.00 ➝ $21.00+8.02%
8/10/2021Bank of America
Jason Gerberry
Lower Price TargetNeutral$41.00 ➝ $22.00+14.70%
8/10/2021Canaccord Genuity
DowngradeBuy ➝ Hold$86.00 ➝ $20.00+9.35%
Difei Yang
Lower Price TargetBuy$70.00 ➝ $29.00+59.69%
8/10/2021The Goldman Sachs Group
DowngradeBuy ➝ Neutral$63.00 ➝ $23.00+26.65%
8/10/2021Wells Fargo & Company
DowngradeOverweight ➝ Equal Weight$60.00 ➝ $25.00+37.67%
8/9/2021Stifel Nicolaus
Lower Price TargetHold$31.00 ➝ $18.00-0.88%
8/9/2021SVB Leerink
M. Foroohar
DowngradeOutperform ➝ Market Perform$64.00 ➝ $20.00+6.61%
7/16/2021Morgan Stanley
Lower Price TargetEqual Weight$36.00 ➝ $35.00+27.13%
7/1/2021Berenberg Bank
DowngradeBuy ➝ Hold$35.00+9.44%
Reiterated RatingHold
3/29/2021Piper Sandler
Boost Price Target$30.00 ➝ $35.00+10.13%
3/29/2021Jefferies Financial Group
Reiterated RatingBuy
Lower Price TargetEqual Weight$31.00 ➝ $27.00+5.39%
2/17/2021Royal Bank of Canada
DowngradeOutperform ➝ Sector Perform
2/17/2021JPMorgan Chase & Co.
DowngradeOverweight ➝ Neutral$76.00 ➝ $39.00+37.13%
D. Nierengarten
DowngradeOutperform ➝ Neutral
12/9/2020Maxim Group
DowngradeBuy ➝ Hold
2/19/2020Raymond James
DowngradeStrong-Buy ➝ Market Perform
2/3/2020Evercore ISI
UpgradeIn-Line ➝ Outperform$86.00 ➝ $100.00+25.49%
Reiterated RatingBuy
Jing He
Reiterated RatingBuy
6/14/2019Piper Jaffray Companies
Tyler Van Buren
Set Price TargetHold$120.00-1.87%
5/16/2019SunTrust Banks
Lower Price TargetBuy$174.00+36.50%
3/22/2019Cantor Fitzgerald
Elemer Piros
Set Price TargetHold$122.00-16.80%
12/3/2018Janney Montgomery Scott
Yun Zhong
Set Price TargetOutperform ➝ Buy$170.00+49.12%
11/14/2018Sanford C. Bernstein
UpgradeMarket Perform ➝ Outperform$155.00+28.87%
(Data available from 9/19/2016 forward. View 10+ years of historical ratings with our analyst ratings screener.)
speech bubbles
speech bubbles

bluebird bio (NASDAQ:BLUE) Analyst Ratings Frequently Asked Questions

What is bluebird bio's consensus rating and price target?

According to the issued ratings of 19 analysts in the last year, the consensus rating for bluebird bio stock is Hold based on the current 17 hold ratings and 2 buy ratings for BLUE. The average twelve-month price target for bluebird bio is $37.81 with a high price target of $93.00 and a low price target of $18.00. Learn more on BLUE's analyst rating history

Do Wall Street analysts like bluebird bio more than its competitors?

Analysts like bluebird bio stock less than the stock of other Medical companies. The consensus rating for bluebird bio is Hold while the average consensus rating for medical companies is Buy. Learn more on how BLUE compares to other companies

Do MarketBeat users like bluebird bio more than its competitors?

MarketBeat users like bluebird bio stock more than the stock of other Medical companies. 74.40% of MarketBeat users gave bluebird bio an outperform vote while medical companies recieve an average of 67.17% outperform votes by MarketBeat users.

Is bluebird bio being downgraded by Wall Street analysts?

Over the previous 90 days, bluebird bio's stock had 5 downgrades by analysts.

Does bluebird bio's stock price have much upside?

According to analysts, bluebird bio's stock has a predicted upside of 46.16% based on their 12-month price targets.

What analysts cover bluebird bio?

This page was last updated on 9/19/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.